nodes	percent_of_prediction	percent_of_DWPC	metapath
Sorafenib—RET—autonomic nervous system—conduct disorder	0.0948	0.181	CbGeAlD
Sorafenib—CDKL3—brain—conduct disorder	0.0331	0.0631	CbGeAlD
Sorafenib—CDKL2—brain—conduct disorder	0.0303	0.0577	CbGeAlD
Sorafenib—MAPK15—brain—conduct disorder	0.0273	0.052	CbGeAlD
Sorafenib—HIPK4—brain—conduct disorder	0.0183	0.035	CbGeAlD
Sorafenib—MAPK11—brain—conduct disorder	0.0162	0.0308	CbGeAlD
Sorafenib—CDK7—brain—conduct disorder	0.0159	0.0303	CbGeAlD
Sorafenib—TAOK2—brain—conduct disorder	0.0158	0.0301	CbGeAlD
Sorafenib—AURKC—brain—conduct disorder	0.0157	0.0298	CbGeAlD
Sorafenib—EPHA6—brain—conduct disorder	0.0145	0.0276	CbGeAlD
Sorafenib—ZAK—brain—conduct disorder	0.0137	0.0262	CbGeAlD
Sorafenib—HIPK3—brain—conduct disorder	0.0134	0.0256	CbGeAlD
Sorafenib—MAP3K19—brain—conduct disorder	0.0132	0.0251	CbGeAlD
Sorafenib—TIE1—brain—conduct disorder	0.0126	0.024	CbGeAlD
Sorafenib—BRAF—brain—conduct disorder	0.0121	0.023	CbGeAlD
Sorafenib—EPHX2—brain—conduct disorder	0.0115	0.022	CbGeAlD
Sorafenib—FLT4—brain—conduct disorder	0.0104	0.0198	CbGeAlD
Sorafenib—FGFR1—brain—conduct disorder	0.0102	0.0195	CbGeAlD
Sorafenib—MAP3K7—brain—conduct disorder	0.0097	0.0185	CbGeAlD
Sorafenib—MKNK2—brain—conduct disorder	0.0094	0.0179	CbGeAlD
Sorafenib—MKNK1—brain—conduct disorder	0.00928	0.0177	CbGeAlD
Sorafenib—RET—brain—conduct disorder	0.00917	0.0175	CbGeAlD
Sorafenib—RALBP1—brain—conduct disorder	0.00849	0.0162	CbGeAlD
Sorafenib—FLT1—brain—conduct disorder	0.00808	0.0154	CbGeAlD
Sorafenib—RAF1—brain—conduct disorder	0.00803	0.0153	CbGeAlD
Sorafenib—EPHB6—brain—conduct disorder	0.00798	0.0152	CbGeAlD
Sorafenib—STK10—brain—conduct disorder	0.00764	0.0146	CbGeAlD
Sorafenib—PDGFRA—brain—conduct disorder	0.00757	0.0144	CbGeAlD
Sorafenib—KDR—brain—conduct disorder	0.00683	0.013	CbGeAlD
Sorafenib—MAP2K5—brain—conduct disorder	0.00683	0.013	CbGeAlD
Sorafenib—CSF1R—brain—conduct disorder	0.00666	0.0127	CbGeAlD
Sorafenib—KIT—brain—conduct disorder	0.00605	0.0115	CbGeAlD
Sorafenib—PDGFRB—brain—conduct disorder	0.00591	0.0113	CbGeAlD
Sorafenib—HTR2C—brain—conduct disorder	0.00498	0.0095	CbGeAlD
Sorafenib—ABCC4—brain—conduct disorder	0.0047	0.00897	CbGeAlD
Sorafenib—HTR2B—brain—conduct disorder	0.00468	0.00892	CbGeAlD
Sorafenib—CYP2C8—brain—conduct disorder	0.00342	0.00651	CbGeAlD
Sorafenib—ABCG2—brain—conduct disorder	0.00332	0.00633	CbGeAlD
Sorafenib—CYP2B6—brain—conduct disorder	0.00306	0.00584	CbGeAlD
Sorafenib—CYP2D6—brain—conduct disorder	0.00228	0.00434	CbGeAlD
Sorafenib—ABCB1—brain—conduct disorder	0.00164	0.00312	CbGeAlD
Sorafenib—ABCG2—Transmembrane transport of small molecules—GABRA2—conduct disorder	0.000775	0.00163	CbGpPWpGaD
Sorafenib—HTR2C—G alpha (q) signalling events—HTR2A—conduct disorder	0.000765	0.00161	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—WASF1—conduct disorder	0.000758	0.00159	CbGpPWpGaD
Sorafenib—CYP1A2—Phase II conjugation—COMT—conduct disorder	0.000754	0.00159	CbGpPWpGaD
Sorafenib—CYP2B6—Biological oxidations—COMT—conduct disorder	0.000749	0.00157	CbGpPWpGaD
Sorafenib—RAF1—Immune System—MB21D1—conduct disorder	0.000744	0.00157	CbGpPWpGaD
Sorafenib—CYP2B6—Biological oxidations—MAOA—conduct disorder	0.000743	0.00156	CbGpPWpGaD
Sorafenib—HTR2B—GPCR downstream signaling—CGA—conduct disorder	0.00074	0.00156	CbGpPWpGaD
Sorafenib—CYP2B6—Metapathway biotransformation—COMT—conduct disorder	0.000738	0.00155	CbGpPWpGaD
Sorafenib—UGT1A9—PPARA activates gene expression—EP300—conduct disorder	0.000738	0.00155	CbGpPWpGaD
Sorafenib—HTR2B—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.000733	0.00154	CbGpPWpGaD
Sorafenib—HTR2B—GPCR ligand binding—DRD4—conduct disorder	0.000733	0.00154	CbGpPWpGaD
Sorafenib—CYP3A5—Biological oxidations—COMT—conduct disorder	0.000732	0.00154	CbGpPWpGaD
Sorafenib—CYP3A5—Biological oxidations—MAOA—conduct disorder	0.000727	0.00153	CbGpPWpGaD
Sorafenib—UGT1A9—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—EP300—conduct disorder	0.000722	0.00152	CbGpPWpGaD
Sorafenib—RALBP1—Signaling Pathways—DRD4—conduct disorder	0.000722	0.00152	CbGpPWpGaD
Sorafenib—CYP3A5—Metapathway biotransformation—COMT—conduct disorder	0.000722	0.00152	CbGpPWpGaD
Sorafenib—KIT—Immune System—POLR3A—conduct disorder	0.000719	0.00151	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—POLR3A—conduct disorder	0.000719	0.00151	CbGpPWpGaD
Sorafenib—FLT4—Signaling Pathways—DRD4—conduct disorder	0.00071	0.00149	CbGpPWpGaD
Sorafenib—EPHX2—Metabolism—COMT—conduct disorder	0.000696	0.00146	CbGpPWpGaD
Sorafenib—EPHX2—Metabolism—MAOA—conduct disorder	0.000691	0.00145	CbGpPWpGaD
Sorafenib—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—conduct disorder	0.000684	0.00144	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—POLR3A—conduct disorder	0.000682	0.00143	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—POLR3A—conduct disorder	0.00068	0.00143	CbGpPWpGaD
Sorafenib—HTR2B—Signaling by GPCR—CGA—conduct disorder	0.000672	0.00141	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—WASF1—conduct disorder	0.000671	0.00141	CbGpPWpGaD
Sorafenib—EPHX2—Metabolism of lipids and lipoproteins—EP300—conduct disorder	0.00067	0.00141	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—CGA—conduct disorder	0.000646	0.00136	CbGpPWpGaD
Sorafenib—CYP3A4—Phase 1 - Functionalization of compounds—MAOA—conduct disorder	0.000636	0.00134	CbGpPWpGaD
Sorafenib—CYP2C8—Biological oxidations—COMT—conduct disorder	0.000634	0.00133	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—CGA—conduct disorder	0.000629	0.00132	CbGpPWpGaD
Sorafenib—CYP2C8—Biological oxidations—MAOA—conduct disorder	0.000629	0.00132	CbGpPWpGaD
Sorafenib—HTR2B—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.000628	0.00132	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—CGA—conduct disorder	0.000628	0.00132	CbGpPWpGaD
Sorafenib—CYP2C8—Metapathway biotransformation—COMT—conduct disorder	0.000625	0.00132	CbGpPWpGaD
Sorafenib—RAF1—TGF-beta Signaling Pathway—EP300—conduct disorder	0.000621	0.00131	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—POLR3A—conduct disorder	0.000613	0.00129	CbGpPWpGaD
Sorafenib—KIT—Immune System—WASF1—conduct disorder	0.000605	0.00127	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—WASF1—conduct disorder	0.000605	0.00127	CbGpPWpGaD
Sorafenib—EPHB6—Developmental Biology—EP300—conduct disorder	0.0006	0.00126	CbGpPWpGaD
Sorafenib—HTR2C—GPCR downstream signaling—CGA—conduct disorder	0.000597	0.00126	CbGpPWpGaD
Sorafenib—HTR2C—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.000592	0.00124	CbGpPWpGaD
Sorafenib—HTR2C—GPCR ligand binding—DRD4—conduct disorder	0.000591	0.00124	CbGpPWpGaD
Sorafenib—MKNK1—Signaling Pathways—DRD4—conduct disorder	0.000588	0.00124	CbGpPWpGaD
Sorafenib—FGFR1—Integrated Pancreatic Cancer Pathway—EP300—conduct disorder	0.000577	0.00121	CbGpPWpGaD
Sorafenib—PDGFRA—Integrated Pancreatic Cancer Pathway—EP300—conduct disorder	0.000575	0.00121	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—WASF1—conduct disorder	0.000574	0.00121	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—WASF1—conduct disorder	0.000573	0.0012	CbGpPWpGaD
Sorafenib—CYP2C19—Biological oxidations—COMT—conduct disorder	0.000566	0.00119	CbGpPWpGaD
Sorafenib—EPHA6—Developmental Biology—EP300—conduct disorder	0.000564	0.00119	CbGpPWpGaD
Sorafenib—CYP2C19—Biological oxidations—MAOA—conduct disorder	0.000562	0.00118	CbGpPWpGaD
Sorafenib—CYP2C19—Metapathway biotransformation—COMT—conduct disorder	0.000558	0.00117	CbGpPWpGaD
Sorafenib—RAF1—Immune System—POLR3A—conduct disorder	0.000546	0.00115	CbGpPWpGaD
Sorafenib—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EP300—conduct disorder	0.000543	0.00114	CbGpPWpGaD
Sorafenib—CYP1A2—Aryl Hydrocarbon Receptor—EP300—conduct disorder	0.000543	0.00114	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—CGA—conduct disorder	0.000542	0.00114	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—CGA—conduct disorder	0.000541	0.00114	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism of lipids and lipoproteins—CGA—conduct disorder	0.000539	0.00113	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—CGA—conduct disorder	0.000536	0.00113	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—DRD4—conduct disorder	0.00053	0.00111	CbGpPWpGaD
Sorafenib—CYP2D6—Biological oxidations—COMT—conduct disorder	0.00052	0.00109	CbGpPWpGaD
Sorafenib—MAPK11—Cellular responses to stress—EP300—conduct disorder	0.00052	0.00109	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—WASF1—conduct disorder	0.000518	0.00109	CbGpPWpGaD
Sorafenib—CYP2D6—Biological oxidations—MAOA—conduct disorder	0.000517	0.00109	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—WASF1—conduct disorder	0.000516	0.00109	CbGpPWpGaD
Sorafenib—CYP2C9—Biological oxidations—COMT—conduct disorder	0.000516	0.00109	CbGpPWpGaD
Sorafenib—CYP2D6—Metapathway biotransformation—COMT—conduct disorder	0.000513	0.00108	CbGpPWpGaD
Sorafenib—CYP2C9—Biological oxidations—MAOA—conduct disorder	0.000512	0.00108	CbGpPWpGaD
Sorafenib—ABCB1—HIF-1-alpha transcription factor network—EP300—conduct disorder	0.00051	0.00107	CbGpPWpGaD
Sorafenib—CYP2C9—Metapathway biotransformation—COMT—conduct disorder	0.000509	0.00107	CbGpPWpGaD
Sorafenib—HTR2C—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.000507	0.00107	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—WASF1—conduct disorder	0.000504	0.00106	CbGpPWpGaD
Sorafenib—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—EP300—conduct disorder	0.000498	0.00105	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—CGA—conduct disorder	0.000488	0.00103	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—CGA—conduct disorder	0.000488	0.00103	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism of lipids and lipoproteins—CGA—conduct disorder	0.000481	0.00101	CbGpPWpGaD
Sorafenib—HTR2B—GPCR ligand binding—HTR2A—conduct disorder	0.000478	0.00101	CbGpPWpGaD
Sorafenib—RALBP1—Signaling Pathways—HTR2A—conduct disorder	0.000471	0.000991	CbGpPWpGaD
Sorafenib—FLT4—Signaling Pathways—HTR2A—conduct disorder	0.000463	0.000975	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—CGA—conduct disorder	0.000463	0.000974	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—CGA—conduct disorder	0.000462	0.000972	CbGpPWpGaD
Sorafenib—RAF1—Integrated Pancreatic Cancer Pathway—EP300—conduct disorder	0.000462	0.000971	CbGpPWpGaD
Sorafenib—RAF1—Immune System—WASF1—conduct disorder	0.00046	0.000967	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—CGA—conduct disorder	0.000456	0.000959	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—CGA—conduct disorder	0.000456	0.000959	CbGpPWpGaD
Sorafenib—CDK7—Cell Cycle, Mitotic—EP300—conduct disorder	0.000446	0.000938	CbGpPWpGaD
Sorafenib—CYP1A2—Biological oxidations—COMT—conduct disorder	0.000441	0.000927	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism of lipids and lipoproteins—CGA—conduct disorder	0.000439	0.000923	CbGpPWpGaD
Sorafenib—CYP1A2—Biological oxidations—MAOA—conduct disorder	0.000438	0.000921	CbGpPWpGaD
Sorafenib—CYP1A2—Metapathway biotransformation—COMT—conduct disorder	0.000435	0.000915	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—WASF1—conduct disorder	0.000434	0.000912	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—WASF1—conduct disorder	0.00043	0.000904	CbGpPWpGaD
Sorafenib—ABCB1—Transmembrane transport of small molecules—GABRA2—conduct disorder	0.000419	0.000881	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—CGA—conduct disorder	0.000416	0.000875	CbGpPWpGaD
Sorafenib—HTR2B—GPCR downstream signaling—DRD4—conduct disorder	0.000414	0.000872	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling by Wnt—EP300—conduct disorder	0.000405	0.000852	CbGpPWpGaD
Sorafenib—CDK7—Cell Cycle—EP300—conduct disorder	0.000399	0.000839	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—CGA—conduct disorder	0.000397	0.000835	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—WASF1—conduct disorder	0.000391	0.000823	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—WASF1—conduct disorder	0.000391	0.000823	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—CGA—conduct disorder	0.000387	0.000814	CbGpPWpGaD
Sorafenib—HTR2C—GPCR ligand binding—HTR2A—conduct disorder	0.000386	0.000812	CbGpPWpGaD
Sorafenib—MKNK1—Signaling Pathways—HTR2A—conduct disorder	0.000384	0.000808	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—CGA—conduct disorder	0.000384	0.000807	CbGpPWpGaD
Sorafenib—HTR2B—Signaling by GPCR—DRD4—conduct disorder	0.000376	0.000791	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism of lipids and lipoproteins—CGA—conduct disorder	0.000375	0.000789	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—WASF1—conduct disorder	0.000371	0.000781	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—CGA—conduct disorder	0.000371	0.00078	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—WASF1—conduct disorder	0.00037	0.000779	CbGpPWpGaD
Sorafenib—KDR—Developmental Biology—EP300—conduct disorder	0.000366	0.000771	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—DRD4—conduct disorder	0.000362	0.000761	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—DRD4—conduct disorder	0.000352	0.000741	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—DRD4—conduct disorder	0.000352	0.00074	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—HTR2A—conduct disorder	0.000346	0.000727	CbGpPWpGaD
Sorafenib—CYP3A4—Biological oxidations—COMT—conduct disorder	0.00034	0.000716	CbGpPWpGaD
Sorafenib—CYP3A4—Biological oxidations—MAOA—conduct disorder	0.000338	0.000711	CbGpPWpGaD
Sorafenib—CYP3A4—Metapathway biotransformation—COMT—conduct disorder	0.000336	0.000706	CbGpPWpGaD
Sorafenib—HTR2C—GPCR downstream signaling—DRD4—conduct disorder	0.000334	0.000703	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—WASF1—conduct disorder	0.000334	0.000702	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CGA—conduct disorder	0.00032	0.000674	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—WASF1—conduct disorder	0.000318	0.000669	CbGpPWpGaD
Sorafenib—MAPK11—Developmental Biology—EP300—conduct disorder	0.000315	0.000663	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—DRD4—conduct disorder	0.000304	0.000639	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—DRD4—conduct disorder	0.000303	0.000638	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—DRD4—conduct disorder	0.0003	0.000632	CbGpPWpGaD
Sorafenib—EPHX2—Metabolism—EP300—conduct disorder	0.000298	0.000628	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—WASF1—conduct disorder	0.000297	0.000625	CbGpPWpGaD
Sorafenib—MKNK1—Disease—EP300—conduct disorder	0.00029	0.000611	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—CGA—conduct disorder	0.000284	0.000597	CbGpPWpGaD
Sorafenib—MAPK11—Innate Immune System—EP300—conduct disorder	0.000278	0.000585	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—CGA—conduct disorder	0.000277	0.000583	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—DRD4—conduct disorder	0.000273	0.000575	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—DRD4—conduct disorder	0.000273	0.000575	CbGpPWpGaD
Sorafenib—HTR2B—GPCR downstream signaling—HTR2A—conduct disorder	0.00027	0.000569	CbGpPWpGaD
Sorafenib—FGFR1—Developmental Biology—EP300—conduct disorder	0.00027	0.000567	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—DRD4—conduct disorder	0.000259	0.000546	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—DRD4—conduct disorder	0.000259	0.000544	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—WASF1—conduct disorder	0.000257	0.00054	CbGpPWpGaD
Sorafenib—ABCC4—Hemostasis—EP300—conduct disorder	0.000252	0.00053	CbGpPWpGaD
Sorafenib—KIT—Innate Immune System—EP300—conduct disorder	0.000251	0.000528	CbGpPWpGaD
Sorafenib—MAP3K7—Innate Immune System—EP300—conduct disorder	0.000251	0.000528	CbGpPWpGaD
Sorafenib—RALBP1—Signaling Pathways—EP300—conduct disorder	0.000249	0.000525	CbGpPWpGaD
Sorafenib—HTR2B—Signaling by GPCR—HTR2A—conduct disorder	0.000245	0.000516	CbGpPWpGaD
Sorafenib—FLT4—Signaling Pathways—EP300—conduct disorder	0.000245	0.000516	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—CGA—conduct disorder	0.00024	0.000505	CbGpPWpGaD
Sorafenib—FGFR1—Innate Immune System—EP300—conduct disorder	0.000238	0.000501	CbGpPWpGaD
Sorafenib—PDGFRA—Innate Immune System—EP300—conduct disorder	0.000237	0.0005	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—HTR2A—conduct disorder	0.000236	0.000496	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—DRD4—conduct disorder	0.000233	0.00049	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—HTR2A—conduct disorder	0.00023	0.000484	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—HTR2A—conduct disorder	0.000229	0.000483	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—DRD4—conduct disorder	0.000222	0.000468	CbGpPWpGaD
Sorafenib—HTR2C—GPCR downstream signaling—HTR2A—conduct disorder	0.000218	0.000459	CbGpPWpGaD
Sorafenib—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—conduct disorder	0.000218	0.000458	CbGpPWpGaD
Sorafenib—RAF1—Developmental Biology—EP300—conduct disorder	0.000216	0.000454	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—CGA—conduct disorder	0.000214	0.000451	CbGpPWpGaD
Sorafenib—PDGFRB—Innate Immune System—EP300—conduct disorder	0.000214	0.00045	CbGpPWpGaD
Sorafenib—RAF1—Hemostasis—EP300—conduct disorder	0.000212	0.000446	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—CGA—conduct disorder	0.000209	0.00044	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—DRD4—conduct disorder	0.000208	0.000437	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—COMT—conduct disorder	0.000206	0.000433	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—COMT—conduct disorder	0.000206	0.000433	CbGpPWpGaD
Sorafenib—CDK7—Disease—EP300—conduct disorder	0.000205	0.00043	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—MAOA—conduct disorder	0.000204	0.00043	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—MAOA—conduct disorder	0.000204	0.00043	CbGpPWpGaD
Sorafenib—MKNK1—Signaling Pathways—EP300—conduct disorder	0.000203	0.000428	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism of lipids and lipoproteins—EP300—conduct disorder	0.000198	0.000417	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—HTR2A—conduct disorder	0.000198	0.000417	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—HTR2A—conduct disorder	0.000198	0.000416	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—CGA—conduct disorder	0.000197	0.000415	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—HTR2A—conduct disorder	0.000196	0.000412	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—CGA—conduct disorder	0.000195	0.000411	CbGpPWpGaD
Sorafenib—RAF1—Innate Immune System—EP300—conduct disorder	0.000191	0.000401	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—EP300—conduct disorder	0.000183	0.000385	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—DRD4—conduct disorder	0.000179	0.000377	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—HTR2A—conduct disorder	0.000178	0.000375	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—HTR2A—conduct disorder	0.000178	0.000375	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—COMT—conduct disorder	0.000175	0.000367	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—MAOA—conduct disorder	0.000173	0.000365	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—COMT—conduct disorder	0.000173	0.000364	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—MAOA—conduct disorder	0.000172	0.000362	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—HTR2A—conduct disorder	0.000169	0.000356	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—HTR2A—conduct disorder	0.000169	0.000355	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—CGA—conduct disorder	0.000167	0.000351	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—EP300—conduct disorder	0.000162	0.000341	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—HTR2A—conduct disorder	0.000152	0.00032	CbGpPWpGaD
Sorafenib—BRAF—Disease—EP300—conduct disorder	0.000148	0.000312	CbGpPWpGaD
Sorafenib—KIT—Immune System—EP300—conduct disorder	0.000146	0.000307	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—EP300—conduct disorder	0.000146	0.000307	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—HTR2A—conduct disorder	0.000145	0.000305	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—EP300—conduct disorder	0.000139	0.000292	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—EP300—conduct disorder	0.000138	0.000291	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—HTR2A—conduct disorder	0.000136	0.000285	CbGpPWpGaD
Sorafenib—KIT—Disease—EP300—conduct disorder	0.000135	0.000284	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—CGA—conduct disorder	0.000129	0.000271	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—COMT—conduct disorder	0.000128	0.000269	CbGpPWpGaD
Sorafenib—FGFR1—Disease—EP300—conduct disorder	0.000128	0.000269	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—EP300—conduct disorder	0.000128	0.000269	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—MAOA—conduct disorder	0.000127	0.000267	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—COMT—conduct disorder	0.000125	0.000263	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—EP300—conduct disorder	0.000125	0.000263	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—EP300—conduct disorder	0.000125	0.000262	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—MAOA—conduct disorder	0.000124	0.000261	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—EP300—conduct disorder	0.000122	0.000256	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—HTR2A—conduct disorder	0.000117	0.000246	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—EP300—conduct disorder	0.000115	0.000242	CbGpPWpGaD
Sorafenib—RAF1—Immune System—EP300—conduct disorder	0.000111	0.000234	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—COMT—conduct disorder	0.000108	0.000228	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—MAOA—conduct disorder	0.000108	0.000226	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—EP300—conduct disorder	0.000105	0.00022	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism of lipids and lipoproteins—EP300—conduct disorder	0.000104	0.00022	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—EP300—conduct disorder	0.000104	0.000218	CbGpPWpGaD
Sorafenib—RAF1—Disease—EP300—conduct disorder	0.000103	0.000216	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—COMT—conduct disorder	9.68e-05	0.000204	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—MAOA—conduct disorder	9.61e-05	0.000202	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—EP300—conduct disorder	9.45e-05	0.000199	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—EP300—conduct disorder	9.45e-05	0.000199	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—COMT—conduct disorder	9.44e-05	0.000199	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—MAOA—conduct disorder	9.38e-05	0.000197	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism of lipids and lipoproteins—EP300—conduct disorder	9.32e-05	0.000196	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—EP300—conduct disorder	8.97e-05	0.000189	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—EP300—conduct disorder	8.94e-05	0.000188	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—COMT—conduct disorder	8.9e-05	0.000187	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—MAOA—conduct disorder	8.84e-05	0.000186	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—EP300—conduct disorder	8.83e-05	0.000186	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—EP300—conduct disorder	8.83e-05	0.000186	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—COMT—conduct disorder	8.82e-05	0.000186	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—MAOA—conduct disorder	8.76e-05	0.000184	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism of lipids and lipoproteins—EP300—conduct disorder	8.49e-05	0.000179	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—EP300—conduct disorder	8.06e-05	0.000169	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—EP300—conduct disorder	7.68e-05	0.000162	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—COMT—conduct disorder	7.54e-05	0.000159	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—EP300—conduct disorder	7.49e-05	0.000158	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—MAOA—conduct disorder	7.49e-05	0.000157	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—EP300—conduct disorder	7.42e-05	0.000156	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism of lipids and lipoproteins—EP300—conduct disorder	7.26e-05	0.000153	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—EP300—conduct disorder	7.18e-05	0.000151	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—EP300—conduct disorder	6.2e-05	0.00013	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—COMT—conduct disorder	5.82e-05	0.000122	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—MAOA—conduct disorder	5.78e-05	0.000122	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—EP300—conduct disorder	5.49e-05	0.000116	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—EP300—conduct disorder	5.37e-05	0.000113	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—EP300—conduct disorder	4.65e-05	9.78e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—EP300—conduct disorder	4.15e-05	8.73e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—EP300—conduct disorder	4.05e-05	8.52e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—EP300—conduct disorder	3.82e-05	8.03e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—EP300—conduct disorder	3.78e-05	7.96e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—EP300—conduct disorder	3.23e-05	6.8e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—EP300—conduct disorder	2.49e-05	5.25e-05	CbGpPWpGaD
